Previous 10 | Next 10 |
Aeglea BioTherapeutics Launches THINK ARGININE™, a Disease Education Initiative to Improve Awareness and Diagnosis of Arginase 1 Deficiency Includes Sponsored Diagnostic Testing and Services for Patients with Suspected Arginase 1 Deficiency PR Newswire A...
Aeglea BioTherapeutics (AGLE) announces that it has completed patient randomization for PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints), the pivotal Phase 3 clinical trial investigating pegzilarginase for the treatment of Arginase 1 Deficiency ((ARG1-D)).ARG1-D is a ...
Aeglea BioTherapeutics Completes Patient Randomization for PEACE, its Pivotal Phase 3 Clinical Trial of Pegzilarginase for the Treatment of Arginase 1 Deficiency Topline Results Expected in the Fourth Quarter of 2021; Target Enrollment Exceeded Pegzilarginase has the Potenti...
Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021 PR Newswire AUSTIN, Texas, April 1, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of hum...
Aeglea BioTherapeutics (AGLE) has signed an agreement with Immedica Pharma AB giving the latter commercialization rights to pegzilarginase for the treatment of Arginase 1 Deficiency in Europe and the Middle East.Under the terms of the agreement, Immedica will make an upfront payment of $21.5 ...
Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East Aeglea receives $21.5 million upfront with up to approximately $130 million in milestone payments and royalties in the...
Aeglea BioTherapeutics (AGLE): FY GAAP EPS of -$1.52 beats by $0.04.Cash, cash equivalents, marketable securities and restricted cash of $148.1MPress Release For further details see: Aeglea BioTherapeutics EPS beats by $0.04
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights Phase 3 PEACE Study Enrollment Expected to Complete in March; Topline Data Expected in Fourth Quarter Received U.S. Rare Pediatric Disease Designation for AGLE-177 for...
Aeglea Biotherapeutics (AGLE) gains 5.5% premarket on disclosing 9.9% stake (4.9M shares) by Baker Bros.Source For further details see: Aeglea Biotherapeutics climbs 5.5% on ownership disclosure
Gainers: [[SNSE]] +17.5%. [[ABCL]] +8.3%. [[AGLE]] +7.6%. [[OLED]] +5.9%. [[EOLS]] +5.4%.Losers: [[CRWD]] -7.0%. [[ARDX]] -6.9%. [[NK]] -6.6%. [[CATB]] -3.2%. [[ISEE]] -3.1%. For further details see: SNSE, AGLE, CRWD and ISEE among after-hours movers
News, Short Squeeze, Breakout and More Instantly...
Aeglea BioTherapeutics Inc. Company Name:
AGLE Stock Symbol:
NASDAQ Market:
Aeglea BioTherapeutics Inc. Website:
Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD PR Newswire Company will begin trading on Nasdaq under trading sy...
2023-11-20 05:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Continued progress across the Company's potentially best-in-class inflammatory bowel disease (IBD) portfolio SPY001, a half-life extended anti-α4β...